抗CD20单克隆抗体联合FcRn拮抗剂治疗多种神经节苷脂抗体阳性的慢性吉兰-巴雷综合征1例

doi:10.3969/j.issn.1006-6233.2025.01.032

摘要
图/表
参考文献
相关文章 (0)

[1] Collet R,Caballero-Avila M,Querol L.Clinical and pathophysiological implications of autoantibodies in autoimmune neuropathies[J].Rev Neurol (Paris),2023,179(8):831-843.
[2] Pascual-Goni E,Fehmi J,Lleixa C,et al.Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy[J].Brain,2021,144(4):1183-1196.
[3] Takemoto K,Kawahara M,Atagi K.Recurrent guillain-barre syndrome associated with the second episode of campylobacter jejuni infection[J].Intern Med,2023,62(20):3037-3041.
[4] 徐杰,乔保俊,宋进,等.鲁西南地区吉兰-巴雷综合征患者常见抗神经节苷脂IgG抗体的种类及临床意义[J].中国神经免疫学和神经病学杂志,2023,30(3):162-168.
[5] Strawbridge J,Fu K A,Chan J,et al.Facial diplegia with paresthesia associated with anti-GD1a antibodies[J].Proc (Bayl Univ Med Cent),2022,35(3):387-388.
[6] Song Y,Zhang Y,Yuki N,et al.Guillain-barre syndrome in eastern China:a study of 595 patients[J].Eur Neurol,2021,28(8):2727-2735.
[7] 张凯华,杨硕,卜淑芳.神经传导阻滞与神经节苷脂抗体在吉兰-巴雷综合征患者短期预后中的评估价值[J].癫痫与神经电生理学杂志,2024,33(1):26-30.
[8] 李健春,陈頔,曹炜航,等.治疗全身型重症肌无力的新生儿Fc受体拮抗剂-艾加莫德α[J].临床药物治疗杂志,2024,22(4):21-25.
[9] Allen J A,Lin J,Basta I,et al.Safety,tolerability,and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE):a multicentre,randomised-withdrawal,double-blind,placebo-controlled,phase 2 trial[J].Lancet Neurol,2024,23(10):1013-1024.
[10] Hauser S L,Zielman R,Das Gupta A,et al.Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis:the ALITHIOS open-label extension[J].Mult Scler,2023,29(11-12):1452-1464.
[11] Wang Z,Zhou X,Zhao N,et al.Neurofascin antibodies in chronic inflammatory demyelinating polyradiculoneuropathy:from intrinsic genetic background to clinical manifestations[J].Neurol Sci,2021,42(6):2223-2233.
[12] Sellebjerg F,Blinkenberg M,Sorensen P S.Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis[J].CNS Drugs,2020,34(3):269-280.